13F Holdings
中文EN

BGLC BioNexus Gene Lab Corp

Services-Medical Laboratories · Nasdaq · SEC CIK 1737523 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-67.3%
TTM net income YoY12.2%
TTM EPS YoY-27.7%
Revenue 3-yr CAGR-32.9%
Net income 3-yr CAGR—

Margins

Gross margin12.3%
Operating margin-81.8%
Net margin-82.4%
FCF margin-27.3%
EBITDA margin-78.2%

Returns

ROE-33.7%
ROA-28.4%
ROIC (approx.)-32.3%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets10.9%
Debt / equity0.00x
Current ratio6.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.33x
Accruals ratio-19.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.42M$9.51M$9.77M$10.93M$13.36M
Cost of revenue$6.34M$8.22M$8.44M$9.67M$11.10M
Gross profit$1.09M$1.29M$1.33M$1.26M$2.27M
R&D expense$50,670$47,511$54,982——
SG&A expense$1.54M$1.83M$2.44M$1.73M$1.28M
Operating income-$2.97M-$1.57M-$2.59M-$291,177$1.06M
Interest expense——$13,929$12,479—
Pretax income-$2.98M-$1.59M-$2.61M-$303,656$1.04M
Income tax$0-$3,494-$21,526-$52,310-$291,283
Net income-$2.98M-$1.60M-$2.63M-$355,966$751,571
EBITDA-$2.85M-$1.47M-$2.51M-$199,750$1.15M
EPS (diluted)—-0.09-0.17——
Weighted avg. shares (diluted)—17.82M15.88M——
Banking
Net interest income——$8,877$7,794—
Balance sheet
Cash & equivalents$2.38M$2.89M$4.52M$2.12M$2.12M
Receivables$505,885$1.38M———
Inventory$676,703$1.39M$1.14M$977,807$1.52M
Current assets$5.45M$7.43M$8.05M$6.02M$7.15M
PP&E, net$1.60M$1.52M$1.51M$1.51M$1.63M
Total assets$9.25M$10.43M$11.40M$8.74M$9.57M
Current liabilities$520,957$1.95M$1.63M$2.00M$2.33M
Total liabilities$637,856$2.11M$1.74M$2.08M$2.39M
Shareholders' equity$8.61M$8.32M$9.66M$6.67M$7.18M
Shares outstanding2.42M1.80M17.67M14.48M171.22M
Cash flow statement
Operating cash flow-$1.84M-$2.09M-$1.82M$551,822$9,161
Capital expenditure$36,971$226,989$149,398$0$3,162
Free cash flow-$1.88M-$2.32M-$1.97M$551,822$5,999
Investing cash flow$944,751$418,202-$1.79M-$450,498-$490,574
Financing cash flow$298,841$3,975$6.27M$108,168-$28,222
Depreciation & amortization$111,873$104,160$83,253$91,427$91,282
Stock-based compensation$794,770$141,000———

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.